Clinical Trials · NCT06075667
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 160
- Start date
- Oct 2023
- Locations
- 33 sites, 6 countries
- Primary endpoint
- Percent Change from Baseline in Body Mass Index (BMI)